nacubactam + meropenem
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gram-negative Bacterial Infections
Conditions
Gram-negative Bacterial Infections
Trial Timeline
Jun 15, 2017 → Aug 10, 2017
NCT ID
NCT03182504About nacubactam + meropenem
nacubactam + meropenem is a phase 1 stage product being developed by Roche for Gram-negative Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03182504. Target conditions include Gram-negative Bacterial Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03182504 | Phase 1 | Completed |
Competing Products
14 competing products in Gram-negative Bacterial Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cefiderocol + Standard of Care | Shionogi | Phase 2 | 52 |
| Cefiderocol | Shionogi | Pre-clinical | 23 |
| Cefiderocol + Standard of Care | Shionogi | Phase 2 | 52 |
| Cefiderocol + Standard of Care | Shionogi | Phase 2 | 52 |
| HRS-8427 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4 | AbbVie | Phase 2 | 52 |
| IMI/REL + Active Control + Oral Switch | Merck | Phase 2/3 | 65 |
| IMI/REL FDC | Merck | Phase 1 | 33 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg | Merck | Phase 1 | 33 |
| Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3 + Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3 | Pfizer | Phase 2 | 51 |
| ATM-AVI + BAT | Pfizer | Phase 2 | 51 |
| tigecycline | Pfizer | Phase 3 | 76 |
| AN3365 + Placebo | Pfizer | Phase 1 | 32 |